Celyad SA (CYAD) Announces Completion of NKR-2 Phase I in AML
Tweet Send to a Friend
Celyad (Nasdaq: CYAD) announced the successful completion of the 21-day safety follow-up of the last patient enrolled at the fourth ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
